Professor Louise Emmett presenting ENZAp clinical trial outcomes on the main stage at Melbourne Convention and Exhibition Centre (MCEC). Her conclusion slide describes overall survival with combination of enzalutamide + LuPSMA compared to enzalutamide alone. Improved deterioration-free survival and health-related quality of life indications for pain, fatigue, physical function, and overall health and quality of life.

Great opening plenary at #ANZSNM2025 covering ENZA-p, #LuPSMA under FDA guidelines, total body PET, and new trends in #NET therapy. ☢️✨

Breaking news podcast - ENZA-P reports OS benefit for combo of enza + LuPSMA. Prof Louise Emmett reports data at ASCO GU and published today in Lancet Oncology. Hosts Declan Murphy & Renu Eapen chat with Louise & Andrew Weickhardt #gu25 #LuPSMA @anzuptrials.bsky.social youtu.be/8xJEXVZZ_0w?...

The @anzuptrials.bsky.social #ENZAp trial outcome presented by Prof Louise Emmett today. #enzalutamide +/- #LuPSMA good news for
#prostatecancer #survival #qualityoflife #cancerresearch #prostate @thelancet.bsky.social

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prost... These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evid...

Great to see the @anzuptrials.bsky.social #TheraP #ClinicalTrial overall survival data published today in Lancet Oncology: #LuPSMA vs #cabazitaxel in #ProstateCancer

www.thelancet.com/journals/lan...